Stock Scorecard

Stock Summary for BioVie Inc - Class A (BIVI) - $1.15 as of 5/12/2025 7:02:08 PM EST

Total Score

12 out of 30

Safety Score

30 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for BIVI

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for BIVI

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for BIVI

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for BIVI

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for BIVI (30 out of 100)

Stock Price Rating (Max of 10) 2
Historical Stock Price Rating (Max of 10) 8
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 2
Book Value to Price (Max of 10) 8
Analyst Buy Ratings (Max of 5) 3
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 6
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for BIVI

BIOVIE ALERT: Bragar Eagel & Squire, P.C. is Investigating BioVie Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - BioVie ( NASDAQ:BIVI ) 5/1/2025 1:00:00 AM
BioVie Initiates SUNRISE-PD Clinical Trial Assessing Bezisterim in Early Parkinson's Disease with First Patient Enrolled 4/16/2025 12:00:00 PM
ALERT: Grabar Law Office Investigates Claims on Behalf of Shareholders of Axsome Therapeutics, Inc. ( NASDAQ: AXSM ) ; BioVie Inc. ( NASDAQ: BIVI ) ; Maison Solutions Inc. ( NASDAQ: MSS ) ; and Virtu Financial Inc. ( NASDAQ: VIRT ) , as Securities Fraud Class Actions Survive Motions to Dismiss - BioVie ( NASDAQ:BIVI ) , Axsome Therapeutics ( NASDAQ:AXSM ) 4/7/2025 11:31:00 AM
New to The Street Show #639 Premieres Nationwide on Bloomberg Television, March 29 at 6:30 PM EST Featuring BioVie, Roadzen, Tonix Pharma, and eXoZymes Inc. 3/29/2025 12:30:00 PM
BIOVIE ALERT: Bragar Eagel & Squire, P.C. is Investigating BioVie Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - BioVie ( NASDAQ:BIVI ) 1/3/2025 2:00:00 AM
( BIVI ) - Analyzing BioVie's Short Interest - BioVie ( NASDAQ:BIVI ) 10/31/2024 5:15:00 PM
UPDATE -- BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules 10/28/2024 8:10:00 PM
BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - BioVie ( NASDAQ:BIVI ) 10/28/2024 7:13:00 PM
BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules 10/28/2024 7:13:00 PM
BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement 10/24/2024 8:10:00 PM

Financial Details for BIVI

Company Overview
Ticker BIVI
Company Name BioVie Inc - Class A
Country USA
Description BioVie Inc., a clinical-stage biotechnology company, is dedicated to the discovery, development, and commercialization of drug therapies in the United States. The company is headquartered in Santa Monica, California.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 12/31/2024
Next Earnings Date 5/12/2025

Stock Price History
Last Day Price 1.15
Price 4 Years Ago 45.00
Last Day Price Updated 5/12/2025 7:02:08 PM EST
Last Day Volume 547,798
Average Daily Volume 627,370
52-Week High 5.08
52-Week Low 0.62
Last Price to 52 Week Low 85.48%

Valuation Measures
Trailing PE N/A
Industry PE 28.89
Sector PE 49.07
5-Year Average PE -11.25
Free Cash Flow Ratio 0.87
Industry Free Cash Flow Ratio 18.95
Sector Free Cash Flow Ratio 31.66
Current Ratio Most Recent Quarter 16.94
Total Cash Per Share 1.32
Book Value Per Share Most Recent Quarter 1.30
Price to Book Ratio 0.83
Industry Price to Book Ratio 38.10
Sector Price to Book Ratio 30.44
Price to Sales Ratio Twelve Trailing Months 0.00
Industry Price to Sales Ratio Twelve Trailing Months 93.45
Sector Price to Sales Ratio Twelve Trailing Months 25.43
Analyst Buy Ratings 2
Analyst Strong Buy Ratings 0

Share Statistics
Total Shares Outstanding 18,452,000
Market Capitalization 21,219,800
Institutional Ownership N/A

Dividends
Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement
Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 36.09%
Reported EPS 12 Trailing Months -3.25
Reported EPS Past Year -1.16
Reported EPS Prior Year -1.53
Net Income Twelve Trailing Months -25,204,032
Net Income Past Year -32,120,533
Net Income Prior Year -50,255,814
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth 77.79%
Operating Margin Twelve Trailing Months 0.00%

Balance Sheet
Total Cash Most Recent Quarter 24,405,517
Total Cash Past Year 23,843,798
Total Cash Prior Year 19,460,883
Net Cash Position Most Recent Quarter 23,555,517
Net Cash Position Past Year -831,156,202
Long Term Debt Past Year 855,000,000
Long Term Debt Prior Year 5,227,270
Total Debt Most Recent Quarter 850,000
Equity to Debt Ratio Past Year 0.02
Equity to Debt Ratio Most Recent Quarter 0.97
Total Stockholder Equity Past Year 15,506,215
Total Stockholder Equity Prior Year 15,340,286
Total Stockholder Equity Most Recent Quarter 23,922,579

Free Cash Flow
Free Cash Flow Twelve Trailing Months -22,022,361
Free Cash Flow Per Share Twelve Trailing Months -1.19
Free Cash Flow Past Year -27,945,028
Free Cash Flow Prior Year -40,252,881

Options
Put/Call Ratio 0.00
Has Options False
Liquidity Rating

Technical Analysis
Yahoo Finance Chart Yahoo Finance Chart
MACD 0.06
MACD Signal 0.01
20-Day Bollinger Lower Band 0.42
20-Day Bollinger Middle Band 1.40
20-Day Bollinger Upper Band 2.38
Beta 1.18
RSI 60.23
50-Day SMA 26.59
150-Day SMA 30.14
200-Day SMA 33.51

System
Modified 5/12/2025 7:02:55 PM EST